International journal of clinical pharmacology and biopharmacy最新文献_第6页

Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks. 比较黑人和白人患者的异烟肼表型，重点是南非黑人。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-07-01

L Eidus, E Glatthaar, M M Hodgkin, E E Nel, H H Kleeberg

引用次数: 0

Evaluation of antihemorrhagic activity of V. F. V. F.抗出血活性的评价。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-07-01

M Marcucci, E Aliboni, A Previtera, A Martini

引用次数: 0

Effect of spironolactone treatment on the renin-aldosterone system during pregnancy. 螺内酯治疗对妊娠期肾素-醛固酮系统的影响。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-07-01

R Lammintausta, R Erkkola

{"title":"Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.","authors":"R Lammintausta, R Erkkola","doi":"","DOIUrl":"","url":null,"abstract":"Ten pregnant patients were treated with spironolactone (100 mg daily) for two weeks. The patients were on a continuous long-term saluretic therapy for pregnancy edema. In addition, a potassium supplementation (30 mmol/day) was given until the beginning of spironolactone treatment. The patients thus treated had a mean urinary aldosterone excretion (dU-Aldo) of more than ten-fold in comparison to that of non pregnant state. Canrenone, the effective conversion product of spironolactone in plasma, reached its steady state level in three days as in non-pregnant subjects. dU-Aldo decreased in two weeks during the spironolactone by 36% (p less than 0.05). The inhibition of aldosterone secretion is thus evident also after a low clinical dose of spironolactone. Urinary potassium excretion (dU-K) decreased during the 1st day (p less than 0.05) and continued to decrease during one week of spironolactone therapy by a total of 21% (p less than 0.001). The decrease in dU-K reflects the cessation of potassium supplements in the beginning of the study. No changes in urinary sodium excretion were found. Plasma renin activity (PRA) increased in one week by 79 per cent and the changes of PRA and dU-Aldo showed inverse correlation (p less than 0.001). In our study natriuresis, cannot explain the increase of PRA. Our study suggests another feedback effect of aldosterone.","PeriodicalId":75937,"journal":{"name":"International journal of clinical pharmacology and biopharmacy","volume":"17 7","pages":"294-8"},"PeriodicalIF":0.0,"publicationDate":"1979-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11694385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protective antiallergic effects of a new coumarin compound (BM 15.100) in experimental asthma. 一种新的香豆素化合物(bm15.100)对实验性哮喘的抗过敏保护作用。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-07-01

E Gonsior, G Schultze-Werninghaus, B Wüthrich

引用次数: 0

The role of bile and pancreatic proteases in the pathogenesis of ischemic enteropathy. 胆汁和胰腺蛋白酶在缺血性肠病发病机制中的作用。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-07-01

G Bounous, J Proulx, G Konok, A Wollin

引用次数: 0

Effects of tolmetin, paracetamol, and of two combinations of tolmetin and paracetamol as compared to placebo on experimentally induced pain. A double blind study. 与安慰剂相比，托美汀、扑热息痛以及托美汀和扑热息痛的两种组合对实验性疼痛的影响。一项双盲研究。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-06-01

G Stacher, P Bauer, I Ehn, E Schreiber

{"title":"Effects of tolmetin, paracetamol, and of two combinations of tolmetin and paracetamol as compared to placebo on experimentally induced pain. A double blind study.","authors":"G Stacher, P Bauer, I Ehn, E Schreiber","doi":"","DOIUrl":"","url":null,"abstract":"Previous studies in animals suggested that a coadministration of the anti-rheumatic/anti-inflammatory agent tolmetin (Tolectin) and of paracetamol potentiates the effects of these two drugs. The present study was carried out to assess whether or not the dosis of tolmetin necessary to obtain an analgesic effect can be reduced when paracetamol is coadministered in a model with experimentally induced pain in healthy human subjects. The effects of tolmetin 200 mg (T 200), paracetamol 400 mg (P 400), tolmetin 150 mg plus paracetamol 300 mg (T 150 + P 300), and of tolmetin 100 mg plus paracetamol 400 mg (T 100 + P 400) on pain threshold to electrical and thermal stimuli and on pain tolerance to electrical stimuli were compared to the effects of placebo under double blind conditions. Each of 20 healthy volunteers received all of the 5 treatments randomised according to four 5 X 5 Latin squares. The results showed that the combination T 100 + P 400 had better analgesic effects than the double dose of tolmetin, T 200, alone, while the effects of P 400 could not be discrminated from placebo. In a sequential t-test the effects of T 100 + P 400 could be discriminated from placebo already after 14 Ss. The effects of T 200, T 150 + P 300, and T 100 + P 400 respectively could not be differentiated, indicating that the dose of tolmetin can be reduced markedly by simultaneous administration of paracetamol without a loss in analgesic potency. Coadministration of tolmetin and paracetamol permits a marked reduction of the dose of tolmetin without any loss of analgesic potency as measured in a model with experimentally induced pain in healthy subjects.","PeriodicalId":75937,"journal":{"name":"International journal of clinical pharmacology and biopharmacy","volume":"17 6","pages":"250-5"},"PeriodicalIF":0.0,"publicationDate":"1979-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11589494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release. 拉贝他洛尔在肾素释放中的α和β肾上腺素受体阻断特性。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-06-01

R Lammintausta, M Koulu, H Allonen

{"title":"Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.","authors":"R Lammintausta, M Koulu, H Allonen","doi":"","DOIUrl":"","url":null,"abstract":"The effect of labetalol, an alpha- and beta-adrenergic receptor blocking antihypertensive, on plasma renin activity (PRA) and the hemodynamics of healthy volunteers at rest and during an ergometric exercise test was studied. Oral doses of 200 and 400 mg labetalol were tested against a placebo in a crossover manner. The labetalol plasma concentrations were determined. Systolic and diastolic blood pressures in the supine position decreased after 400 mg labetalol as did the response of the heart rate to exercise. The lower dose decreased the resting heart rate, but had no effect on the heart rate during exercise. The ergometric exercise induced an increase in PRA which was partly inhibited after 200 mg labetalol in a manner similar to that induced by beta-blockers in our earlier studies. After 400 mg labetalol PRA was already increased at one hour at sitting rest and this higher basal level was maintained for four hours. After this higher dose of labetalol the reaction of PRA to exercise was not significantly inhibited. In renin release the vasodilating alpha-blockade thus dominated the beta-blocking property of labetalol at the dose which decreased the blood pressure.","PeriodicalId":75937,"journal":{"name":"International journal of clinical pharmacology and biopharmacy","volume":"17 6","pages":"240-43"},"PeriodicalIF":0.0,"publicationDate":"1979-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11260775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacology of a combination of bronchodilators. 支气管扩张剂联合用药的临床药理学。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-06-01

L Casali, C Grassi, C Rampulla, A Rossi

引用次数: 0

Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma. 吡特罗、沙丁胺醇和安慰剂气雾剂治疗支气管哮喘的比较研究。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-06-01

H M Beumer

引用次数: 0

Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. 呋喃妥因新同系物呋喃妥因在人体志愿者体内的药代动力学。

International journal of clinical pharmacology and biopharmacy Pub Date : 1979-06-01

P Männistö, P Karttunen

{"title":"Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers.","authors":"P Männistö, P Karttunen","doi":"","DOIUrl":"","url":null,"abstract":"The human pharmacokinetics of a nitrofurantoin congener furagin was studied after a single oral dose of 200 mg and during a 9-day continuous treatment with a dose of 100 mg t.i.d. The same dose of nitrofurantoin served as a reference medication. In the acute cross-over phase food greatly speeded up and atropine somewhat retarded the absorption of furagin, but the total absorption remained virtually unchanged as judged from the unchanged AUC values. The furagin concentrations in serum remain several hours above the MIC concentrations of many pathogenic bacteria. Despite the high concentrations in serum, the urine levels of furagin were generally lower than those of nitrofurantoin. The 24 hr recoveries in urine were 8--13% for furagin and about 36% for nitrofurantoin. In the prolonged trial furagin was absorbed and excreted in the same way as in the acute trial. On the 9th day the concentrations in serum and urine were higher than on the first day. The urinary concentrations of both furagin and nitrofurantoin always remained well above the MIC values of the most susceptible bacteria. Several volunteers complained of nightly cramps in their calves after taking furagin for some days, otherwise the side effects were minimal.","PeriodicalId":75937,"journal":{"name":"International journal of clinical pharmacology and biopharmacy","volume":"17 6","pages":"264-70"},"PeriodicalIF":0.0,"publicationDate":"1979-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11673888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0